Cellular immunotherapy in multiple myeloma
Manh-Cuong VoDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, KoreaThangaraj Jaya LakshmiResearch Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, KoreaSung‐Hoon JungDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, KoreaDuck ChoDepartment of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaHye-Seong ParkResearch Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, KoreaTan-Huy ChuResearch Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, KoreaHyunju LeeVaxCell-Bio Therapeutics, Hwasun, College of Industrial Science, Kongju National University, Yesan, KoreaHyeoung‐Joon KimDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, KoreaSang‐Ki KimDepartment of Companion and Laboratory Animal Science, College of Industrial Science, Kongju National University, Yesan, KoreaJe‐Jung LeeDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea
2019en
ABI
Аннотация
In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor's escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendritic cells, natural killer cells, and genetically engineered T-cells represent a new therapeutic era. The application of these treatments is growing rapidly, based on their capacity to eradicate MM. In this review, we summarize recent progress in cellular immunotherapy for MM and its future prospects.
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0